Abstract
Background COVID-19 vaccines, while providing protection against hospitalization, could inadvertently increase selection pressure on new immune-escape variants, impacting case hospitalization rate (CHR).
Methods Using epidemiological and genomic sequence data, we calculated daily state-level CHR and the proportion of Omicron mutations in the United States during the first Omicron wave (between December 11, 2021, and March 22, 2022). We derived mathematical formulas to link evolution responses to an increasing population immunity with lagged regression models. Using mediation analysis, together with generalized linear mixed models and distributed lag nonlinear models, we assessed how natural selection, shaped by vaccine coverage, impacts CHR.
Results The model showed that increasing vaccination coverage from 45% to 70% contributed to a reduction in CHR from 5.8% to 4.4%. Part of the reduction resulted from direct vaccine protection (OR: 0.85, p-value=0.012). However, the higher vaccination coverage was correlated with a 20% increase in the proportion of BA.1/BA.1.1-associated mutations. As the Omicron variants were less severe than their predecessors (Delta), CHR further reduced (OR: 0.87, p-value<0.001). Marginally, this could reduce CHR from 5.8% to 5.1% via the adaptation of Omicron variants as marginal effect without accounting for direct vaccine protection.
Conclusions The study offers new insight into vaccine strategies for reducing hospitalization risk by shortening [or maintaining] the circulation of more [or less] virulent variants among infectious diseases. Continuous monitoring of variant evolution, including their virulence, is critical.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
City University of Hong Kong [#9610416].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos